Literature DB >> 24584301

Protective effects of daphnetin on sodium taurocholate‑induced severe acute pancreatitis in rats.

Zhi-Yong Liu1, Jiao Liu2, Kai-Liang Zhao1, Li-Kun Wang1, Qiao Shi1, Teng Zuo1, Tian-Yi Liu1, Liang Zhao1, Wei-Xing Wang1.   

Abstract

Severe acute pancreatitis (SAP) is the sudden onset of pancreatic inflammation, which is characterized by edema, acinar cell necrosis, hemorrhage and severe inflammation of the pancreas and is associated with a high mortality rate. Daphnetin has been shown to alleviate organ injury in a variety of preclinical animal models of coagulation disorders. The aim of the present study was to investigate the protective effects of daphnetin on severe acute pancreatitis in a rat model. Severe acute pancreatitis in the rat model was induced by retrograde infusion of 5% sodium taurocholate (1 ml/kg) into the bile-pancreatic duct. Daphnetin (4 mg/kg) was administered intraperitoneally at 30 min prior to the infusion of sodium taurocholate. The severity of pancreatitis was evaluated by various analyses of serum amylase and lipase, tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) levels, myeloperoxidase (MPO) activity and malondialdehyde (MDA) content, as well as by histological grading. The levels of TNF-α and IL-1β in the serum were measured by ELISA. The results revealed that the daphnetin-treated SAP rat group (SAP-D) exhibited a lower pathological score of the pancreas compared with the SAP group (SAP). Further analyses demonstrated that the SAP-D group had lower levels of serum amylase, lipase and pro-inflammatory cytokines, including TNF-α and IL-1β, and a decreased MPO activity and MDA content 3, 6 and 12 h subsequent to the infusion of sodium taurocholate compared with the SAP group (SAP). These findings indicated that daphnetin exerted a protective function in the SAP rat model. Therefore, daphnetin may be considered as a potential compound for the therapy and prevention of acute pancreatitis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24584301     DOI: 10.3892/mmr.2014.1995

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  5 in total

1.  Daphnetin Ameliorates Experimental Autoimmune Encephalomyelitis Through Regulating Heme Oxygenase-1.

Authors:  Dan Wang; Bo Zhu; Xiaoyi Liu; Qin Han; Weihong Ge; Wenping Zhang; Yin Lu; Qinan Wu; Liyun Shi
Journal:  Neurochem Res       Date:  2020-01-16       Impact factor: 3.996

2.  Daphnetin Protects against Cerebral Ischemia/Reperfusion Injury in Mice via Inhibition of TLR4/NF-κB Signaling Pathway.

Authors:  Jia Liu; Qianxue Chen; Zhihong Jian; Xiaoxing Xiong; Lingmin Shao; Tong Jin; Xiqun Zhu; Lei Wang
Journal:  Biomed Res Int       Date:  2016-12-29       Impact factor: 3.411

Review 3.  Toll-Like Receptor 2 Signaling and Current Approaches for Therapeutic Modulation in Synucleinopathies.

Authors:  Ian F Caplan; Kathleen A Maguire-Zeiss
Journal:  Front Pharmacol       Date:  2018-05-04       Impact factor: 5.810

4.  Daphnetin ameliorates acute lung injury in mice with severe acute pancreatitis by inhibiting the JAK2-STAT3 pathway.

Authors:  Shujun Yang; Yaodong Song; Qiaofang Wang; Yanna Liu; Zhongwei Wu; Xiaojia Duan; Yan Zhang; Xiuqian Bi; Yuanzhang Geng; Sanyang Chen; Changju Zhu
Journal:  Sci Rep       Date:  2021-06-01       Impact factor: 4.379

5.  Daphnetin suppresses experimental abdominal aortic aneurysms in mice via inhibition of aortic mural inflammation.

Authors:  Shiyun Xie; Li Ma; Hongliang Guan; Su Guan; Lijuan Wen; Chanchan Han
Journal:  Exp Ther Med       Date:  2020-10-15       Impact factor: 2.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.